SBC Medical Group (NASDAQ:SBC) Sets New 12-Month High - Time to Buy?

Key Points

• SBC Medical Group shares reached a new 52-week high, rising 9.2% to about $5.03 after trading as high as $5.09.
• Analyst sentiment is mixed: two analysts rate the stock Buy and one rates it Sell, resulting in an overall “Hold” rating and an average price target of $8.50.
• The company exceeded quarterly revenue expectations with $49.19 million but missed EPS estimates, reporting $0.10 versus the anticipated $0.12; institutional investors own 60.82% of its shares.

Shares of SBC Medical Group Holdings Incorporated (NASDAQ:SBC - Get Free Report) hit a new 52-week high during trading on Monday . The company traded as high as $5.09 and last traded at $5.0270, with a volume of 47270 shares traded. The stock had previously closed at $4.75.

Analysts Set New Price Targets

A number of brokerages have recently commented on SBC. Wall Street Zen raised shares of SBC Medical Group from a "buy" rating to a "strong-buy" rating in a research report on Saturday. BTIG Research reiterated a "buy" rating and issued a $8.00 price target on shares of SBC Medical Group in a report on Thursday, August 13th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of SBC Medical Group in a report on Wednesday, August 19th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $8.50.

SBC Medical Group Trading Up 9.2%

The company has a quick ratio of 3.27, a current ratio of 3.31 and a debt-to-equity ratio of 0.09. The stock's 50 day moving average is $3.66 and its two-hundred day moving average is $3.53. The company has a market capitalization of $533.26 million, a PE ratio of 11.03 and a beta of 0.63.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported $0.10 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.02). SBC Medical Group had a net margin of 27.99% and a return on equity of 18.47%. The business had revenue of $49.19 million for the quarter, compared to analysts' expectations of $45.37 million. As a group, sell-side analysts predict that SBC Medical Group Holdings Incorporated will post 0.44 EPS for the current fiscal year.

Hedge Funds Weigh In On SBC Medical Group

Large investors have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in SBC Medical Group during the second quarter worth $446,000. Two Sigma Securities LLC purchased a new position in shares of SBC Medical Group in the 2nd quarter valued at $66,000. Bank of America Corp DE bought a new position in shares of SBC Medical Group in the 2nd quarter worth $35,000. BlackRock Inc. bought a new position in shares of SBC Medical Group in the 2nd quarter worth $2,846,000. Finally, Deutsche Bank AG bought a new position in shares of SBC Medical Group in the 2nd quarter worth $58,000. Institutional investors own 60.82% of the company's stock.

SBC Medical Group Company Profile

SBC Medical Group NASDAQ: SBC is a Japan-based medical services and management company focused primarily on the aesthetic medicine sector. Through its affiliated medical corporations and clinic network, the company supports the operation of facilities offering cosmetic surgery, cosmetic dermatology and related elective treatments.

The company provides a range of management and operational services to affiliated clinics, including branding and marketing, staff recruitment and training, purchasing, information technology, administrative support and business consulting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.